Alice Cole

Alice Cole

Auto-generated profile, based on publicly available information

Alice Cole

Department of Rheumatology, University College London Hospital , London, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Open access
PDF file
ACAlice Cole
Alice Cole
VOVoon H. Ong
Voon H. Ong
CDChristopher P. Denton
Christopher P. Denton
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) with a mortality of 20% at 6 months. Once the leading cause of mortality in scleroderma (SSc), it remains a serious complication, often necessitating level three care for patients affected. Whilst renal outcomes have significantly improved following the advent of angiotensin-converting enzyme inhibitor (ACEi) therapy, SRC remains a precarious challenge for clinicians, due to lack of preventative measures and the fact that patients can rapidly decline despite best medical management. Large cohort studies spanning decades have allowed clear identification of phenotypes particularly at risk of developing SRC thus allowing enhanced monitoring and early identification in those individuals. Novel urinary biomarkers for renal disease in SSc may offer a new window for early identification of SRC patients and response to treatment. Multiple studies have demonstrated increased activity of complement pathways in SRC with some anecdotal cases exhibiting serological response to treatment with eculizumab where ACEi and therapeutic plasma exchange (TPE) were not successful. Endothelin-1 blockade, a therapeutic strategy in other SSc vasculopathies, has shown potential as a target but clinical trials are yet to show a clear treatment benefit. Clear guidelines for the management of SRC are in place to standardise care and facilitate early collaboration between rheumatology and renal physicians. Outcomes following renal transplant have improved but the mortality of SRC remains high, indicating the need for continued exploration of the mechanisms precipitating and exacerbating SRC in order to develop novel therapies.

2 March 2022 in Journal of Autoimmunity
Verified
Journal Article
Closed access
ACAlice Cole
Alice Cole
RTRhys Thomas
Rhys Thomas
NGNina Goldman
Nina Goldman
KHKevin Howell
Kevin Howell
KCKuntal Chakravarty
Kuntal Chakravarty
VOVoon H. Ong
Voon H. Ong

3 June 2024 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
PDF file
ACAlice Cole
Alice Cole
AJAli S Jawad
Ali S Jawad
Dear Editor, We share Hawarden et al. concern regarding training in metabolic bone disease (MBD) [ 1]. To address this important issue, we organised a 3-hour session in MBD in the regular training programme for rheumatology trainees in the North Thames Region in May 2023. It was attended by 23 rheumatology trainee doctors. A number of consultants and trainees from care of the elderly medicine and endocrinology also attended. The programme was designed to be interactive, clinical and practical, covering as many aspects of MBD ( Table 1) to help trainees achieve competence in the management of osteoporosis and a number of other rare MBD by the end of their training. The choice of topics was based on the published curriculum [ 2], trainee feedback and the experience of one the authors (ASJ) who has been running the MBD module of the MSc (endocrinology) QMUL course over the past 16 years.